{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:51:36Z","timestamp":1783993896532,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.vaccine.2018.07.056","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T11:03:22Z","timestamp":1533294202000},"page":"5580-5590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response"],"prefix":"10.1016","volume":"36","author":[{"given":"Xinle","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuishu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronzo B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart P.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"McVoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford M.","family":"Snapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2018.07.056_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jcv.2009.10.007","article-title":"Congenital cytomegalovirus: Public health action towards awareness, prevention, and treatment","volume":"46","author":"Demmler-Harrison","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0010","article-title":"Knowledge and awareness of congenital cytomegalovirus among women","volume":"80383","author":"Jeon","year":"2006","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0015","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMra050700","article-title":"Newborn hearing screening\u2013a silent revolution","volume":"354","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.07.056_b0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.pcl.2012.12.008","article-title":"Congenital cytomegalovirus infection: new prospects for prevention and therapy","volume":"60","author":"Swanson","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.vaccine.2018.07.056_b0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2018.07.056_b0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0035","first-page":"23","article-title":"Prevention of maternal cytomegalovirus infection: current status and future prospects","volume":"2","author":"Nyholm","year":"2010","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.vaccine.2018.07.056_b0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee","volume":"39","author":"Arvin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.056_b0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.vaccine.2018.07.056_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2006.03.005","article-title":"Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART)","volume":"37","author":"Steininger","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0060","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00005792-198603000-00005","article-title":"Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases","volume":"65","author":"Horwitz","year":"1986","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2018.07.056_b0065","series-title":"Vaccines for the 21st century: a tool for decisionmaking","author":"Stratton","year":"2001"},{"key":"10.1016\/j.vaccine.2018.07.056_b0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Krause","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0075","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.07.056_b0080","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00018-008-7570-z","article-title":"Entry of herpesviruses into mammalian cells","volume":"65","author":"Heldwein","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2018.07.056_b0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10409230802058320","article-title":"Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme","volume":"43","author":"White","year":"2008","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0042-6822(92)90200-9","article-title":"Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface","volume":"191","author":"Compton","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.07.056_b0095","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.80.2.710-722.2006","article-title":"Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion","volume":"80","author":"Ryckman","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0105","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/v4050800","article-title":"Herpes virus fusion and entry: a story with many characters","volume":"4","author":"Eisenberg","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2018.07.056_b0110","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0115","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1099\/vir.0.81921-0","article-title":"Role of human cytomegalovirus UL131A in cell type-specific virus entry and release","volume":"87","author":"Adler","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0120","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0125","doi-asserted-by":"crossref","first-page":"E4997","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine","volume":"110","author":"Freed","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.07.056_b0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1128\/JVI.05354-11","article-title":"Mutational mapping of pUL131A of human cytomegalovirus emphasizes its central role for endothelial cell tropism","volume":"86","author":"Schuessler","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0135","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.vaccine.2014.03.057","article-title":"Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease","volume":"32","author":"Fu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0140","first-page":"90","article-title":"A recombinant subunit vaccine approach to HCMV vaccine development","volume":"23","author":"Spaete","year":"1991","journal-title":"Transplant Proc"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2018.07.056_b0145","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0150","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.07.056_b0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.virol.2012.09.024","article-title":"HCMV gB shares structural and functional properties with gB proteins from other herpesviruses","volume":"435","author":"Sharma","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.07.056_b0160","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1016\/j.vaccine.2015.10.078","article-title":"A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells","volume":"33","author":"McVoy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jim.2007.02.001","article-title":"Novel microneutralization assay for HCMV using automated data collection and analysis","volume":"322","author":"Abai","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.07.056_b0170","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1016\/j.vaccine.2015.10.110","article-title":"RT-qPCR-based microneutralization assay for human cytomegalovirus using fibroblasts and epithelial cells","volume":"33","author":"Wang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00430-015-0411-4","article-title":"Human cytomegalovirus: taking the strain","volume":"204","author":"Wilkinson1","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0180","doi-asserted-by":"crossref","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"Potzsch","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2018.07.056_b0185","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1073\/pnas.0810530106","article-title":"Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B","volume":"106","author":"Backovic","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.07.056_b0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1126548","article-title":"Crystal structure of glycoprotein B from herpes simplex virus 1","volume":"313","author":"Heldwein","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.07.056_b0195","doi-asserted-by":"crossref","first-page":"12924","DOI":"10.1128\/JVI.01750-10","article-title":"Structural basis of local, pH-dependent conformational changes in glycoprotein B from herpes simplex virus type 1","volume":"84","author":"Stampfer","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0200","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1128\/JVI.74.3.1383-1392.2000","article-title":"Characterization of a panel of insertion mutants in human cytomegalovirus glycoprotein B","volume":"74","author":"Singh","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1128\/jvi.58.1.185-191.1986","article-title":"Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus","volume":"58","author":"Britt","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0210","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1128\/jvi.66.11.6747-6754.1992","article-title":"Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116)","volume":"66","author":"Britt","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/jvi.63.1.403-410.1989","article-title":"Processing of the gp55-116 envelope glycoprotein complex (gB) of human cytomegalovirus","volume":"63","author":"Britt","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0220","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1128\/jvi.69.11.7015-7022.1995","article-title":"Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding","volume":"69","author":"Billstrom","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0225","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1128\/JVI.76.12.6073-6082.2002","article-title":"Disulfide bond configuration of human cytomegalovirus glycoprotein B","volume":"76","author":"Lopper","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0230","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1128\/JVI.78.15.8333-8341.2004","article-title":"Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion","volume":"78","author":"Lopper","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1469-0691.12449","article-title":"Cytomegalovirus vaccine: phase II clinical trial results","volume":"20","author":"Rieder","year":"2014","journal-title":"Clin Microbiol Infec"},{"key":"10.1016\/j.vaccine.2018.07.056_b0240","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.056_b0245","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.vaccine.2013.07.010","article-title":"Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model","volume":"32","author":"Schleiss","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0250","doi-asserted-by":"crossref","first-page":"e1005227","DOI":"10.1371\/journal.ppat.1005227","article-title":"Crystal Structure of the human cytomegalovirus glycoprotein B","volume":"11","author":"Burke","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2018.07.056_b0255","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1038\/ncomms9176","article-title":"Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody","volume":"6","author":"Chandramouli","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.07.056_b0260","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1128\/jvi.62.9.3309-3318.1988","article-title":"Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)","volume":"62","author":"Britt","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/CVI.00662-13","article-title":"Enveloped virus-like particle expression of human cytomegalovirus glycoprotein b antigen induces antibodies with potent and broad neutralizing activity","volume":"21","author":"Kirchmeier","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0270","doi-asserted-by":"crossref","first-page":"19755","DOI":"10.1073\/pnas.1115861108","article-title":"High-resolution human cytomegalovirus transcriptome","volume":"108","author":"Gatherer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.07.056_b0275","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1099\/vir.0.79888-0","article-title":"Genetic content of wild-type human cytomegalovirus","volume":"85","author":"Dolan","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0280","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/j.1460-2075.1986.tb04606.x","article-title":"Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus","volume":"5","author":"Cranage","year":"1986","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2018.07.056_b0285","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0042-6822(88)90071-2","article-title":"Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage","volume":"167","author":"Spaete","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.07.056_b0290","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0295","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.07.056_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.07.056_b0305","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/v6031346","article-title":"HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex","volume":"6","author":"Zydek","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2018.07.056_b0310","first-page":"89","article-title":"Neutralizing antibodies to the human cytomegalovirus gH\/gL pentamer potently block primary cytotrophoblast","author":"Chiuppesi","year":"2015","journal-title":"Infection J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0315","doi-asserted-by":"crossref","first-page":"e1006601","DOI":"10.1371\/journal.ppat.1006601","article-title":"Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus","volume":"13","author":"Bootz","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.07.056_b0320","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0325","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","article-title":"A novel tetrameric gp350 1\u2013470 as a potential Epstein-Barr virus vaccine","volume":"31","author":"Cui","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.056_b0330","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-017-0038-0","article-title":"Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB\/MF59 vaccination","volume":"2","author":"Li","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2018.07.056_b0335","doi-asserted-by":"crossref","first-page":"e02033","DOI":"10.1128\/JVI.02033-16","article-title":"Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH\/gL\/pUL128-131 pentameric complex","volume":"91","author":"Ha","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.07.056_b0340","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.07.056_b0345","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18310636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18310636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:28:30Z","timestamp":1759400910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18310636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":69,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0264410X18310636"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}